References
- Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903.
- Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25:1700–1721.
- Murdaca G, Colombo B, Puppo F. Anti-TNF-α inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol. 2009;22:557–565.
- Humira®. Prescribing information. Available from: http://www.rxabbvie.com/pdf/humira.pdf
- Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6:469–478.
- Guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product, U.S. Food and Drug Administration (FDA). Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf
- Guidelines on the Evaluation of Biosimilar Products, Republic of Korea. Ministry of Food and Drug Safety (MFDS). Available from: http://www.mfds.go.kr/eng/eng/download.do;jsessionid=1G1QR0t7aL9tTtl5gw0vau8Gxe8GjdXgIjc7At8rrdQ0DEVMQV6NZFVTWdMVhDqN?boardCode=17840&boardSeq=70199&fileSeq=1
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. European Medicines Agency (EMA). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
- Domjan A, Kakuk P, Sandor J. The Helsinki declaration at 50 years: comments on the 2013 modifications. Lege Artis Med. 2014;24:152–158.
- QuantiFERON®-TB - P010033 Online [eLetter]. Gutman SI. U.S. Food and Drug Administration (FDA) CDHR. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf//p010033a.pdf
- Adalimumab Product Approval Information. U.S. Food and Drug Administration (FDA). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125057s110_ClinPharmR.pdf
- Shin D, Kim Y, Kim YS, et al. A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference Product (Remicade®) in healthy subjects. BioDrugs. 2015;29:381–388.
- Benucci M, Gobbi FL, Meacci F, et al. Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins. Biologics Targets Ther. 2015;9:7.
- van Kuijk AW, de Groot M, Stapel SO, et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69:624–625.
- Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921–926.
- Hyland E, Mant T, Vlachos P, et al. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects. Br J Clin Pharmacol. 2016;82(4):983–993.
- Yi SJ, Kim SE, Park M-K, et al. Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®). BioDrugs. 2012;26:177–184.